|
11. |
DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1 |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 968-974
Ojo2 Akinlolu,
Wolfe3 Robert,
Held2,3 Philip,
Port2,3,4 Friedrich,
Schmouder2,4,5 Robert,
Preview
|
|
摘要:
Delayed graft function (DGF) may be associated with diminished kidney allograft survival. We studied the risk factors that lead to nonimmediate function of a renal allograft and the consequences of DGF on short- and long-term renal transplant survival.Data from the U.S. Renal Data System were used to measure the relationships among cold ischemia time, delayed graft function, acute rejection, and graft survival in 37,216 primary cadaveric renal transplants (1985-1992). These relationships were investigated using the unconditional logistic and Cox multivariate regression methods.Cold ischemia time was strongly associated with DGF, with a 23% increase in the risk of DGF for every 6 hr of cold ischemia (P<0.001). Acute transplant rejection occurred more frequently in grafts with delayed function (37% vs. 20%; odds ratio=2.25,P=0.001). DGF was independently predictive of 5-year graft loss (relative risk=1.53,P<0.001). The presence of both early acute rejection and DGF portended a dismal 5-year graft survival rate of 35%. Zero-HLA mismatch conferred a 10-15% improvement in 1- and 5-year graft survival regardless of early functional status of the allograft. However, the 5-year graft survival rate in HLA-mismatched kidneys without DGF was significantly higher than that of zero-mismatched kidneys with DGF (63% vs. 51%;P<0.001).DGF independently portends a significant reduction in short- and long-term graft survival. Delayed function and early rejection episodes exerted an additive adverse effect on allograft survival. The deleterious impact of delayed function is comparatively more severe than that of poor HLA matching.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
12. |
LONG-TERM PROGNOSIS OF RENAL TRANSPLANTATION AFTER PREEMPTIVE TREATMENT OF CYTOMEGALOVIRUS INFECTION |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 974-976
Akposso Kodzo,
Rondeau Eric,
Haymann Jean-Philippe,
Peraldi Marie-Noëlle,
Marlin Christiane,
Sraer1 Jean-Daniel,
Preview
|
|
摘要:
A role for cytomegalovirus (CMV) infection in the etiologies of acute and chronic rejection in renal allograft recipients has been suggested. We previously reported that preemptive treatment of CMV infection with ganciclovir in kidney transplant patients was safe and effective. We now present a retrospective analysis of 169 consecutive renal transplant patients, of whom 87 (51.5%) received preemptive treatment with ganciclovir (CMV(+) group). No patient died of CMV infection. Actuarial graft and patient survival rates were not different between the CMV(+) and the CMV(-) groups (graft survival: 68% and 69%; patient survival: 89% and 88%, respectively). At the end of the study, the mean plasma creatinine levels were not statistically different between the two groups (185±13 and 166±12 μmol/L for the CMV(+) group and the CMV(-) group, respectively). These results suggest that preemptive treatment of CMV infection with ganciclovir may prevent the CMV-induced renal injury and graft loss.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
13. |
A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1 |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 977-983
Pirsch2 John,
Miller Joshua,
Deierhoi Mark,
Vincenti Flavio,
Filo Ronald,
Preview
|
|
摘要:
Background.Tacrolimus (FK506), a macrolide molecule that potently inhibits the expression of interleukin 2 by T lymphocytes, represents a potential major advance in the management of rejection following solid-organ transplantation. This randomized, open-label study compared the efficacy and safety of tacrolimus-based versus cyclosporine-based immunosuppression in patients receiving cadaveric kidney transplants.Methods.A total of 412 patients were randomized to tacrolimus (n=205) or cyclosporine (n=207) after cadaveric renal transplantation and were followed for 1 year for patient and graft survival and the incidence of acute rejection.Results.One-year patient survival rates were 95.6% for tacrolimus and 96.6% for cyclosporine (P=0.576). Corresponding 1-year graft survival rates were 91.2% and 87.9% (P=0.289). There was a significant reduction in the incidence of biopsy-confirmed acute rejection in the tacrolimus group (30.7%) compared with the cyclosporine group (46.4%,P=0.001), which was confirmed by blinded review, and in the use of antilymphocyte therapy for rejection (10.7% and 25.1%, respectively;P<0.001). Impaired renal function, gastrointestinal disorders, and neurological complications were commonly reported in both treatment groups, but tremor and paresthesia were more frequent in the tacrolimus group. The incidence of posttransplant diabetes mellitus was 19.9% in the tacrolimus group and 4.0% in the cyclosporine group (P<0.001), and was reversible in some patients.Conclusions.Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations. Tacrolimus was associated with a higher incidence of neurologic events, which were rarely treatment limiting, and with posttransplant diabetes mellitus, which was reversible in some patients.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
14. |
ACCELERATED ACUTE REJECTION OF AN APPARENT A2RENAL ALLOGRAFT IN AN O RECIPIENTReport of a Case with Flow Cytometric Analysis |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 984-988
Pins1,2 Michael,
Saidman1 Susan,
Cosimi3 A.,
Jennings1 Linda,
Stowell1 Christopher,
Preview
|
|
摘要:
We report a case of accelerated acute rejection of a renal allograft from a presumed ABO histo-blood group A2donor in an O recipient, in which all of the published criteria for compatibility had been met. Flow cytometric analysis of the A and H antigen expression on the kidney donor's erythrocytes suggested that this donor did not have an A2phenotype, but rather another subgroup of A. Some of the reported cases of accelerated acute rejection of A2renal allografts in O recipients may have resulted from mis-application of the results of standard lectin agglutination to the transplant setting. The current case suggests that a more sophisticated method of ABO phenotyping, such as erythrocyte flow cytometric analysis, may be necessary in the transplant setting.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
15. |
IMMUNOLOCALIZATION OF ACIDIC FIBROBLAST GROWTH FACTOR AND RECEPTORS IN THE TUBULOINTERSTITIAL COMPARTMENT OF CHRONICALLY REJECTED HUMAN RENAL ALLOGRAFTS1 |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 988-995
Kerby2 Jeffrey,
Luo2 Kang,
Ding2 Qiang,
Tagouri3 Yahia,
Herrera3,4 Guillermo,
Diethelm2 Arnold,
Thompson2,5 John,
Preview
|
|
摘要:
Tubular damage and loss associated with interstitial inflammation and fibrosis may be the most important determinants in chronic renal allograft rejection. To elucidate potential pathophysiologic mechanisms associated with tubulointerstitial lesions, we examined the expression of a fibrogenic cytokine, acidic fibroblast growth factor (FGF-1) and its high-affinity receptors, in both relevant renal transplant controls (n=5) and tissue from patients (n=19) who underwent nephrectomy after graft loss, secondary to chronic rejection. In situ hybridization and immunohistochemical analyses demonstrated minimal expression of FGF-1 mRNA and protein in the tubulointerstitial compartment of the normal human kidney. In contrast, tubulointerstitial lesions in kidney allografts experiencing chronic rejection demonstrated the exaggerated appearance of both FGF-1 protein and mRNA in resident inflammatory and tubular epithelial cells. Patterns of staining were consistent throughout tubular compartments and did not appear to be localized to any particular region. The tubulointerstitium in kidneys with findings of chronic rejection also exhibited increased immunodetection of proliferating cell nuclear antigen in the tubular epithelium, inflammatory cell infiltrate, and neovascular structures. The enhanced appearance of FGF-1 and readily detectable fibroblast growth factor receptors suggests that this polypeptide mitogen may serve as an important mediator of growth and repair responses, associated with development of angiogenesis and tubulointerstitial lesions during chronic rejection of human renal allografts.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
16. |
PANCREATITIS-ASSOCIATED PROTEIN: A PUTATIVE MARKER FOR PANCREAS GRAFT REJECTION |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 995-1003
van der Pijl1,2 Johan,
Boonstra1 Joke,
Barthellemy3 Sandrine,
Smets4 Yves,
Hermans5 Jo,
Bruijn6 Jan,
de Fijter1 Johan,
Daha1 Mohamed,
Dagorn3 Jean-Charles,
Preview
|
|
摘要:
Background.Graft rejection is one of the major causes of graft loss after pancreas transplantation. Pancreatitis-associated protein (PAP) is synthesized by the pancreas due to pancreatic inflammation and has shown to be a good serum marker for injury of the pancreas. It may also be potentially useful in the early recognition of rejection and may thus improve pancreas survival.Methods.We retrospectively evaluated PAP as an early serum marker of pancreas graft rejection in a cross-sectional study in which immunohistochemical analysis of pancreas biopsies was undertaken using antibodies against PAP. PAP concentrations were also measured in sera of blood donors and in patients with renal failure, renal replacement therapy, kidney transplantation alone, and simultaneous pancreas-kidney transplantation.Results.All patients had elevated PAP serum levels compared with blood donors (median PAP: 22 ng/ml, range: 5-75 ng/ml;P<0.0001). Patients on renal replacement therapy had higher values than patients with renal failure (median: 420 ng/ml and 150 ng/ml, respectively). There was a strong inverse correlation between PAP levels and creatinine clearance (P<0.001). PAP values in simultaneous pancreas-kidney transplantation patients with histological rejection were significantly higher than values in those who were clinically stable (median: 925 ng/ml and 322 ng/ml, respectively;P=0.006).Rejection was significantly associated with PAP staining of acinar cell surface. There was also a significant correlation between surface positivity of staining and serum PAP levels (P=0.008). No positive PAP staining was observed in concurrently collected biopsies of renal allografts undergoing rejection.Conclusions.Serum PAP levels appear to strongly correlate with creatinine clearance measurements. In patients with a pancreas-kidney transplantation, PAP may prove to be a useful biological and histological marker of pancreatic graft rejection.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
17. |
DECREASED CYTOTOXIC ACTIVITY OF NATURAL KILLER CELLS IN KIDNEY ALLOGRAFT RECIPIENTS TREATED WITH HUMAN HLA-DERIVED PEPTIDE |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 1004-1011
Giral1,2 Magali,
Cuturi1,3 Maria-Cristina,
Nguyen4 Jean-Michel,
Josien2,3 Régis,
Dantal2 Jacques,
Floc'h5 Robert,
Buelow6 Roland,
Pouletty6 Philippe,
Soulillou2,3,7 Jean-Paul,
Preview
|
|
摘要:
Peptides derived from a conserved region (aa 75-84) of HLA class I, overlapping the supertypic HLA-BW4/BW6 antigen region, have been shown to exhibit nonallele restricted immunosuppressive properties in rats and mice, prolonging survival of major histocompatibility complex-mismatched allografts. Furthermore, HLA-B7 peptides inhibit alloreactive cytotoxic cells, and both HLA-B7 and HLA-B2702 peptides inhibit natural killer (NK) cytotoxicity in vivo. In this article, we report on a randomized, controlled study of the safety and pharmacokinetics of HLA-B2702-derived peptide in human recipients of a first kidney allograft. Escalating doses of HLA-B2702 were compared with doses of placebo controls. No toxicity and no immunization against the peptide were noted. Although the study was not designed as an efficacy trial, patients who received the high-dose protocol (7 mg/kg) did experience more rejection episodes, but this was not statistically significant when compared with control patients. Interestingly, in human recipients, as previously observed in rodents, administration of the peptide was associated with a statistically significant decrease in the cytotoxicity of NK cells against K562 targets (P<0.001). As these peptides correspond to a region of the HLA class I molecule that interacts with the newly described NK receptors for class I, their mode of action through interaction with such receptors is discussed. As a peptide of the same sequence from HLA-B7 blocks both NK and alloreactive T cell cytotoxicity, it is possible that, in humans too, both types of cytotoxic cells are affected by this peptide. The biological significance of these observations should be confirmed in future controlled studies with a larger patient population.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
18. |
ASSOCIATION BETWEEN HLA-DPB1 MATCHING AND 1-YEAR REJECTION-FREE GRAFT SURVIVAL IN HIGH-RISK CORNEAL TRANSPLANTATION |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 1011-1016
Munkhbat1,2 Batmunkh,
Hagihara1,3 Masao,
Sato3 Tadayuki,
Tsuchida3 Fumiko,
Sato3 Kaoru,
Shimazaki4 Jun,
Tsubota4 Kazuo,
Tsuji1,5 Kimiyoshi,
Preview
|
|
摘要:
We analyzed the effect of matching for HLA class II alleles on corneal graft outcome in a single-center, retrospective study from January 1991 through April 1996. The study involved 81 transplant recipients at high and low risk of corneal graft rejection, who were typed by the polymerase chain reaction-restriction fragment length polymorphism method and who completed at least 1-year of follow-up. The DRB1, DQB1, and DPB1 alleles were analyzed together and transplant recipients were subdivided into groups with matching (one to four alleles matched in the high risk or one to five alleles matched in the low risk) and without matching (no allele matched) for HLA class II. A significantly higher rate of 1-year rejection-free graft survival was revealed in high-risk transplant recipients with matching, compared with those without matching (P=0.0238). We have shown that matching for at least one HLA class II allele was actually beneficial in high-risk transplants. An analysis of matching for each allele separately, detected that only HLA-DPB1 matching was significantly associated with a higher rate of 1-year rejection-free graft survival in high-risk transplant recipients with matching (one or two alleles matched) compared with those without matching (no allele matched) (P=0.0139). In particular, matching for one DPB1 allele was significantly beneficial compared with no matching (P=0.0140). There was no significant effect of HLA-DRB1 and -DQB1 matching (P=0.3177 andP=0.2878, respectively). Furthermore, a strong association between DPB1 matching and 1-year rejection-free graft survival was observed in DRB1-incompatible high-risk transplant recipients (P=0.0308). Nevertheless, no significant effect of DPB1 matching was detected in DQB1-incompatible transplant recipients. Our findings indicate that HLA class II DNA typing is clinically relevant for corneal transplant recipients and that especially HLA-DPB1 matching has a beneficial effect in high-risk corneal transplantation.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
19. |
EXPRESSION OF CTLA4-Ig BY BIOLISTICALLY TRANSFECTED MOUSE ISLETS PROMOTES ISLET ALLOGRAFT SURVIVAL1 |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 1017-1021
Gainer2 Anita,
Korbutt2 Gregory,
Rajotte2,3 Ray,
Warnock2 Garth,
Elliott4,5 John,
Preview
|
|
摘要:
Background.Localized delivery of immunosuppressive molecules, limited to the graft site, may allow transplantation of tissue in the absence of systemic immunosuppressive agents. We tested whether purified mouse islets that had been engineered to produce human CTLA4-Ig locally at the graft site could survive in allogeneic recipients receiving no systemic immunosuppression.Methods.CBA (H2k) islets were subjected to biolistic (gene gun) transfection with a cDNA encoding human CTLA4-Ig under control of the human cytomegalovirus immediate early promoter. After 40-48 hr of culture, the transfected islets (500 per recipient) were transplanted beneath the renal capsule of alloxan-induced diabetic BALB/c (H2d) recipients.Results.Control grafts (n=10) consisting of islets biolistically transfected with the expression plasmid alone (i.e., no gene inserted) survived for 12.8±3.6 (mean ± SD) days. In contrast, islets transfected with CTLA4-Ig (n=12) survived 66.8±61.5 days (P=0.01), with 50% demonstrating functional survival until follow-up was concluded at 50 (n=2), 130 (n=2), or 165 (n=2) days. Immunohistochemistry on grafts that survived long term showed well-granulated, insulin-positive islets lying adjacent to, but not infiltrated by, dense aggregates of mononuclear cells.Conclusions.Transfection of allogeneic mouse islets with human CTLA4-Ig results in prolonged allograft survival. Although on histology mononuclear cells are present in the area of the transfected graft, they do not appear to infiltrate or destroy the islet graft.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
20. |
INVOLVEMENT OF BOTH THE CLASSICAL AND ALTERNATE PATHWAYS OF COMPLEMENT IN AN EX VIVO MODEL OF XENOGRAFT REJECTION |
|
Transplantation,
Volume 63,
Issue 7,
1997,
Page 1021-1025
Romanella1 Margarita,
Aminian1 Atousa,
Adam2 William,
Pearse1 Martin,
d'Apice1,3 Anthony,
Preview
|
|
摘要:
Background.It is now generally accepted that complement activation is critical for the hyperacute rejection of xenografts. Activation of the classical pathway as the result of the interaction of xenoreactive IgM xenoantibodies with the vascular endothelium has been observed in all species combinations examined to date. A number of studies using a variety of species combinations have also implicated alternate pathway involvement; however, these studies do not enable a conclusion to be drawn as to whether the alternate pathway can be activated in the complete absence of classical pathway activation.Methods.In this study, human plasma was depleted of both C1q and factor D and then reconstituted with purified C1q or factor D to restore the classical and alternate complement pathways, respectively. The ability of these modified plasmas to prosecute hyperacute rejection was then examined using an ex vivo isolated mouse heart perfusion model based on the Langendorff system.Results and Conclusions.In the mouse to human species combination, both the classical and alternate pathways of complement are independently capable of initiating complement activation and mediating xenograft rejection.
ISSN:0041-1337
出版商:OVID
年代:1997
数据来源: OVID
|
|